RxDoctor Payments Data

Thomas Zwick

Foot & Ankle Surgery · Miami, FLNPI 1043217235

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Organogenesis Inc. accounts for 90.5% of it on its own, with 44 other manufacturers making up the rest. 2025 is the largest year on record at $53,932, 4.7 times the $11,400 reported in 2019. Among foot & ankle surgery clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$108,190in general payments, 2019–2025

Across 333 payments — averaging $324.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$98K
  • Medline Industries LP$3K
  • Treace Medical Concepts, Inc.$1K
  • Smith+Nephew$985
  • AbbVie$810
  • Musculoskeletal Transplant Foundation Inc.$783
  • plus $3K from 39 others

What the payments were for

  • Consulting fees$28,65526%
  • Speaking & faculty fees$60,30356%
  • Travel & lodging$8,1928%
  • Food & beverage$11,01810%
  • Gifts$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$108,190 in reported general payments places this provider in the 95th percentile of 850 foot & ankle surgery providers in Florida.

See all foot & ankle surgery providers in Florida

Medicare billing

Part B allowed, 2024
$205,407
Medicare patients
305
Services billed
1,823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QutenzaCapsaicin/Skin Cleanser18$60,830
Ciclopirox69$2,830
Econazole Nitrate30$1,214
Ketoconazole65$1,150
Clobetasol Propionate17$797
Mupirocin92$566
Ammonium Lactate11$302
Pregabalin18$286
Ibuprofen16$210
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$158
Levofloxacin30$143
Doxycycline Hyclate12$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GRT US Holding, Inc.Qutenza$419$60,83018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 850 foot & ankle surgery providers in Florida.

Other foot & ankle surgery in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →